Oestradiol positron emission tomography (PET) scans in metastatic breast cancer:investigation of utility of assessing disease burden and treatment response

Not Applicable

Recruiting

• Conditions: metastatic hormone receptor positive breast cancer; Cancer - Breast

• Registration Number: ACTRN12621001588886
• Lead Sponsor: Fiona Stanley Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-11-19
• Last Update Posted: 31 October 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

ER positive metastatic breast cancer patient as defined as IHC >30% for ER who are either treatment naïve in the metastatic setting, or who have been determined to have progressed on previous treatment and are planned to commence a further line of treatment. Those with either ductal or lobular subtype will be included. The number of ductal patients included will be capped at five.

Exclusion Criteria

Life expectancy less than 6 months, unable to give informed consent, unable to comply with required scanning schedule. May include conditions that increase the risk to the participant, that interfere with the participants ability to give informed consent or interfere with a participant’s ability to comply.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of information obtained between oestradiol and standard FDG PET scan at time of initial investigation[baseline (during diagnostic workup)]

Secondary Outcome Measures

Name	Time	Method
Comparison of information obtained between oestradiol and standard FDG PET scan on follow-up assessment to assess response[2 and 6 month follow-up]